Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma.
about
Roles of Akt and SGK1 in the Regulation of Renal Tubular TransportMaximising the potential of AKT inhibitors as anti-cancer treatmentsRole of Akt-independent mTORC1 and GSK3β signaling in sublethal NMDA-induced injury and the recovery of neuronal electrophysiology and survivalSystematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data.Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer.Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.AKT in cancer: new molecular insights and advances in drug development.Innovation in non-Hodgkin lymphoma drug discovery: what needs to be done?Novel agents in classical Hodgkin lymphoma.Advances in the understanding and management of T-cell prolymphocytic leukemia.Recent advances in understanding and managing T-cell lymphoma.Relapsed/refractory Burkitt lymphoma and HIV infection.Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapies.AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity.Comparative High-Resolution Transcriptome Sequencing of Lymphoma Cell Lines and de novo Lymphomas Reveals Cell-Line-Specific Pathway Dysregulation.Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies.Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.Actionable Metabolic Pathways in Heart Failure and Cancer—Lessons From Cancer Cell Metabolism.
P2860
Q26780484-0DBF3FA4-0A79-443F-B658-23B0FB448045Q28072254-EBFABD06-541D-4CD6-8B5D-A26A1217CD84Q33685626-97EF7FC3-F36F-4900-860F-AE5840AAFC57Q33766729-66D43D69-A581-4478-8E37-1341822F7910Q38685006-D947E487-87B8-4363-94C8-8269D286A7BCQ38743320-42B3E53C-DF6D-4BC0-B8A3-8B06AC83C34BQ38819164-E71C5A22-4B55-4EE2-BFE8-98334188F3A1Q38846044-7BBD7978-C52A-4EA3-90CC-A6ED8B75825BQ38939419-E4704FFA-48A7-4528-9767-AF90FD54F8A5Q39187452-B2D67740-E738-4294-A881-B3273B598EAFQ47113632-519255FC-A8FB-4C8C-A81B-7AE793469E7EQ47131247-8F1263BF-854B-4FFB-96F0-49D6570527EFQ47562321-812B1D75-A36F-43EA-A0E0-9383906E088EQ50097295-9EAD6AEF-7757-4C40-B535-7D0E4751309BQ51736090-20BDC1D7-04DB-4D31-9E8E-2522B48DC50DQ52576433-41540251-D1B0-4772-A711-7DEFD8B2E3BFQ54982413-7DE0B263-31A6-41F7-87DA-396D7E25B258Q55281964-C915ECF7-F40A-4A59-8537-404FFE0A46F3Q55401962-E549D81F-1DB9-4957-904A-9CB921AFACFF
P2860
Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 July 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase II study of an AKT inhib ...... lapsed or refractory lymphoma.
@en
Phase II study of an AKT inhib ...... lapsed or refractory lymphoma.
@nl
type
label
Phase II study of an AKT inhib ...... lapsed or refractory lymphoma.
@en
Phase II study of an AKT inhib ...... lapsed or refractory lymphoma.
@nl
prefLabel
Phase II study of an AKT inhib ...... lapsed or refractory lymphoma.
@en
Phase II study of an AKT inhib ...... lapsed or refractory lymphoma.
@nl
P2093
P2860
P356
P1476
Phase II study of an AKT inhib ...... lapsed or refractory lymphoma.
@en
P2093
Amanda Copeland
Anas Younes
Felipe Samaniego
Jorge Romaguera
Larry W Kwak
Luis Fayad
Michael Wang
Michelle Fanale
Nathan Fowler
P2860
P304
P356
10.1111/BJH.13603
P407
P577
2015-07-27T00:00:00Z